GNMSF Stock News Genmab A/S Dkk (GNMSF) 39.1000 07/26/2014 1

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Genmab A/S Dkk (GNMSF) 39.1000 $GNMSF

Second Quarter 2014 Net Sales Figures for Arzerra(r)
GlobeNewswire - Wed Jul 23, 6:11AM CDT
Company Announcement

Genmab Announces Phase III Study of Daratumumab in Front Line Multiple Myeloma
GlobeNewswire - Fri Jul 18, 8:18AM CDT
-- New Phase III study of daratumumab in front line multiple myeloma

Esophageal Cancer Therapeutic Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j6z3g6/esophageal_cancer) has announced the addition of the "Esophageal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Esophageal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Esophageal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Esophageal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Amgen Inc. - GlaxoSmithKline plc - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Novartis AG - Ono Pharmaceutical Co., Ltd. - CTI BioPharma Corp. - Genmab A/S - Advaxis, Inc. - Immunomedics, Inc. - Takara Bio Inc. - Synta Pharmaceuticals Corp. - Transgene Biotek Limited - Supratek Pharma Inc. - Glycotope GmbH - Hutchison MediPharma Limited - Advantagene, Inc. - CerRx, Inc. - Cerulean Pharma, Inc. - MacroGenics, Inc. - Merrimack Pharmaceuticals, Inc. - Omnitura Therapeutics Inc. - Omeros Corporation - Oncolys BioPharma Inc. - ImmunoFrontier, Inc. - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Mebiopharm Co., Ltd. - Kite Pharma, Inc For more information visit http://www.researchandmarkets.com/research/j6...eal_cancer

Genmab to Receive Milestone Payment in DuoBody Platform Collaboration with Janssen
GlobeNewswire - Mon Jul 14, 8:59AM CDT
Genmab A/S (OMX:GEN) announced today it has reached a milestone in its DuoBody technology platform collaboration with Janssen Biotech, Inc. ("Janssen" , triggering a $3 million milestone payment. The milestone payment is for pre-clinical progress with a DuoBody product candidate targeting two inflammatory mediators, proteins which play a key role in major autoimmune diseases.

Johnson & Johnson to Make $25M Milestone Payment to Genmab - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 08, 12:10PM CDT
The payment was triggered by progress in an ongoing phase III study on experimental cancer treatment, daratumumab.

Genmab Reaches USD 25 Million Milestone in Daratumumab Collaboration with Janssen
GlobeNewswire - Mon Jul 07, 9:24AM CDT
Company Announcement

GSK and Genmab Receive EU Authorization for Arzerra(tm) (ofatumumab) as First-Line Treatment for Chronic Lymphocytic Leukemia (CLL) in Combination with Chlorambucil or Bendamustine for Patients Ineligible for Fludarabine-based Therapy
GlobeNewswire - Thu Jul 03, 8:39AM CDT
Company Announcement

GSK and Genmab announce top-line results from a Phase III study of ofatumumab versus physicians' choice for bulky fludarabine-refractory CLL
GlobeNewswire - Fri Jun 27, 1:27PM CDT
Company Announcement

Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2014
M2 - Tue Jun 10, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ch2twj/diffuse_large) has announced the addition of the "Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diffuse Large B-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diffuse Large B-Cell Lymphoma and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Seattle Genetics, Inc. - Genentech, Inc. - MedImmune, LLC - Gilead Sciences, Inc. - Merck & Co., Inc. - Infinity Pharmaceuticals, Inc. - Celltrion, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - ImmunoGen, Inc. - Genmab A/S - Celgene Corporation - Incyte Corporation - Immunomedics, Inc. - Idera Pharmaceuticals, Inc. - Portola Pharmaceuticals, Inc. - Pharmacyclics, Inc. For more information visit http://www.researchandmarkets.com/research/ch...fuse_large

Genmab Announces DuoBody and HexaBody Platform Collaboration With Undisclosed Biotechnology Company
GlobeNewswire - Wed Jun 04, 1:27AM CDT
Company Announcement

Genmab Announces Ofatumumab Development Plans in RRMS and NMO
GlobeNewswire - Fri May 30, 10:05AM CDT
Company Announcement

GSK and Genmab Receive CHMP Positive Opinion for Arzerra(tm) in Combination with Chlorambucil or Bendamustine as a First-line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL) Who Are Not Eligible for Fludarabine-based Therapy
GlobeNewswire - Fri May 23, 8:22AM CDT
Company Announcement

Global Squamous Cell Carcinoma Therapeutics Pipeline Review 2014
M2 - Tue May 20, 9:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/72tfpz/squamous_cell) has announced the addition of the "Squamous Cell Carcinoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Squamous Cell Carcinoma and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Squamous Cell Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Squamous Cell Carcinoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Squamous Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Boehringer Ingelheim GmbH - Novartis AG - Genmab A/S - Celgene Corporation - Clinuvel Pharmaceuticals Limited - Oncolytics Biotech Inc. - Oryzon Genomics S.A. - Hutchison MediPharma Limited - Merrimack Pharmaceuticals, Inc. - Neotropix, Inc. - Axelar AB - Onconova Therapeutics, Inc. - Omeros Corporation - Cellceutix Corporation - Cannabis Science, Inc. - Oncovir, Inc. - Genextra S.p.a. - Bexion Pharmaceuticals, LLC. - AbbVie Inc. Drug Profiles - afatinib - paclitaxel albumin-bound - AXL-1717 - pelareorep - rigosertib sodium - afamelanotide - boanmycin hydrochloride [docetaxel] - CIGB-128 - DAC-0060 - Poly-ICLC - BYL-719 - LJM-716 - interleukin-15 - Antibody Drug Conjugate for Squamous Cell Tumor - irinotecan sucrosofate liposomal - Kevetrin - CUV-9900 - BXQ-350 - CS-TATI-1 - CS-S/BCC-1 - TF-011-Monomethyl Auristatin E - AMXT-1501 eflornithine - Allogenic Mesenchymal Stem Cells - HMPL-453 - NTX-500 - GPR87 Antagonist for Cancer - GPR39 Antagonist for Esophageal Squamous Cell Carcinoma and Obesity-Related Type-2 Diabetes - Monoclonal Antibody For Squamous Cell Cancer - Drugs for Cutaneous Squamous Cell Carcinoma (cSCC) For more information visit http://www.researchandmarkets.com/research/72...amous_cell

GSK and Genmab Announce Topline Results from a Pivotal Head to Head Study of Ofatumumab in Combination With Chemotherapy vs Rituximab in Combination with Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
GlobeNewswire - Mon May 19, 1:22PM CDT
Company Announcement

Genmab Reaches $22 Million Milestone in Daratumumab Collaboration with Janssen
GlobeNewswire - Wed Mar 26, 5:58PM CDT
Company Announcement

Genmab Announces Phase III Study of Daratumumab in Relapsed or Refractory Multiple Myeloma
GlobeNewswire - Tue Mar 04, 11:48PM CST
Company Announcement

Genmab 2013 Annual Report
GlobeNewswire - Tue Mar 04, 10:23AM CST
Genmab A/S (Copenhagen:GEN) today published its Annual Report for 2013. Below is a summary from the report of business progress and financial performance for the year, and financial outlook for 2014. The full report is attached as a PDF file and can be found on the investor section of the company's website, www.genmab.com.

Arzerra(R) Fourth Quarter and Full Year 2013 Net Sales Figures
GlobeNewswire - Wed Feb 05, 6:15AM CST
Company Announcement

Major Shareholder Announcement
GlobeNewswire - Wed Jan 29, 12:57PM CST
Company Announcement

Can Genmab (GNMSF) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 02, 7:47AM CST
Genmab could be an interesting play for investors because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lieda Shadwick’s Career Education Work Earns 2026 Honor

Updated Category News Views 0

Twenty-six years in classrooms is not the sort of accomplishment that needs fireworks to carry weight. Lieda A. Shadwick’s recognition as The Inner Circle’s 2026 Educator of the Year points to a career built around a stubbornly important idea: students need more than academic vocabulary if they are going to navigate work, leadership, and business with any confidence....

Continue Reading
V2’s FOAS Bets on Candid Ad Sales Operator Dialogue

Updated Category News Views 180

Ad sales rarely gets fixed by another ballroom panel, and V2 seems to know it. Its new Future of Ad Sales, or FOAS, forum is built around a simpler premise: put senior operators in a small room, keep vendors and conference theatrics out of the way, and let people compare the ugly real-world details of running revenue machines. Announced November 19, 2026, FOAS is an...

Continue Reading
Insta360 Tests Holiday Demand With $170 Gear Discounts

Updated Category News Views 166

A discount banner can reveal plenty about a hardware brand's priorities, and Insta360's latest Black Friday push is plainly built to put more of its ecosystem into customers' hands. The company is advertising savings of up to US$170 across cameras, gimbals, microphones, webcams, and accessories, with the promotion available for a limited time through its own store and...

Continue Reading
Home Values Need More Than an Algorithm and Hope Today

Updated Category News Views 69

A house can look like a clean number on a screen right up until an actual buyer walks through it and notices the tired roof, the sharp kitchen remodel, or the traffic rattling past the front door. That gap between a digital estimate and a real transaction is the whole point of the recent HelloNation discussion featuring Lawton, Oklahoma, real estate experts Pam Marion and...

Continue Reading
NetEase Margins Hold Firm as Game Revenue Slips Again

Updated Category News Views 65

A game publisher can look tired at the top line and still be doing plenty right underneath the hood. NetEase’s third-quarter 2026 report is that kind of animal: revenue eased, yet costs behaved, profit rebounded from the prior quarter, and the balance sheet remains absurdly well stocked. For investors in NASDAQ:NTES, this was not a clean victory lap. It was a reminder...

Continue Reading
Live Nation Tests Creator Content With Morgan Jay Series

Updated Category News Views 135

A comedian turning crowd work into songs is hardly a boardroom event, but this one has a useful wrinkle: Live Nation Studios put financing behind it. Morgan Jay and Austin-based agency Hello Party launched Music Therapy with Morgan Jay on YouTube on November 18, with Kam Patterson opening the season. The show pairs Jay and celebrity guests for loose conversation,...

Continue Reading
Hope Charities Makes Care Funding Easier to Track Online

Updated Category News Views 72

A treatment bill can wreck a household long before a diagnosis does. That is the uncomfortable reality behind Hope Charities' new Access to Care website, a centralized resource meant to show people in the bleeding disorders community when diagnosis-specific charitable assistance funds are available. This is not flashy technology, nor should it be treated like some grand...

Continue Reading
OFRM Recall Leaves Investors Facing Hard Questions

Updated Category News Views 60

Nothing wrecks a young consumer brand’s glow faster than a recall involving toddlers, and Once Upon A Farm has just learned that lesson in the ugliest possible way. On November 2, 2026, shares of NYSE:OFRM fell 37% to close at $9.44. That left the stock roughly 47% below its $18 IPO price. Those are not the garden-variety bruises of a weak quarter. That is the market...

Continue Reading
Holland America Puts 2028 Alaska Demand on Display

Updated Category News Views 123

Alaska’s interior is where a cruise brochure either earns its keep or gets exposed. Holland America Line is opening bookings for 2028 Alaska Cruisetours nearly two years ahead, tying a coast-and-land product to the reimagined Oosterdam’s Alaska debut. That is not merely another itinerary release. It is a fairly deliberate attempt to sell a bigger, longer and...

Continue Reading
Africa Tech Awards Put Infrastructure Back in Focus

Updated Category News Views 82

Twelve trophies in Cape Town tell a more useful story than most glossy technology forecasts ever manage to. The Africa Tech Festival Awards 2026, announced on November 19 during the event's 29th annual gathering, cut across connectivity, telecoms, AI, cybersecurity, data centres, cloud, fintech, startups and enterprise transformation. That breadth matters. Africa's...

Continue Reading

Top 5 Most Recently Viewed Articles

Alstom Expands High-Speed Rail in Morocco with Avelia Trains

Updated Category News Views 422

Alstom Enhances Moroccan Rail Network Alstom, a leader in innovative transportation solutions, has announced an exciting partnership with the Moroccan National Railway Office to supply a fleet of 18 state-of-the-art Avelia Horizon high-speed trains. This €781 million investment marks a significant milestone for both Alstom and Morocco, as it aims to improve rail...

Continue Reading
Freddie Mac's Innovative Offering of $707 Million in Loans

Updated Category News Views 157

Freddie Mac Launches New Securitization Initiative MCLEAN, Va. — Freddie Mac (OTCQB: FMCC) has taken a significant step in bolstering its financial strategies with the announcement of its latest securitization of approximately $707 million. This initiative focuses on re-performing loans (RPLs) and is part of Freddie Mac's ongoing efforts to manage its mortgage-related...

Continue Reading
Innovative Partnership for Sustainable Aviation Fuel Production

Updated Category News Views 251

Exploring New Horizons in Sustainable Aviation Fuel In a groundbreaking collaboration, Haffner Energy, LanzaJet, and LanzaTech have come together to pave the way for the production of Sustainable Aviation Fuel (SAF) from biomass residues. These three industry leaders are equipped with complementary technologies that can significantly enhance the SAF production value...

Continue Reading
Exploring Microchip Technology's Advancements at UBS Conference

Updated Category News Views 175

Microchip Technology's Presentation Highlights at UBS Conference Microchip Technology Incorporated, a prominent figure in the embedded solutions arena, has something exciting planned at an upcoming event. The company, identified by its ticker symbol NASDAQ:MCHP, is preparing to showcase its innovative offerings at the UBS Global Technology and AI Conference. This...

Continue Reading
Bonaccord Capital Partners Achieves $1.6 Billion Milestone

Updated Category News Views 285

Bonaccord Capital Partners Secures $1.6 Billion for BCP II DALLAS — P10, Inc. (NYSE: PX), a distinguished player in private markets solutions, proudly announced the successful closure of its Bonaccord Capital Partners II fund with an impressive $1.6 billion in commitments. This achievement not only surpasses the fund's initial target of $1.25 billion but also marks a...

Continue Reading